Last reviewed · How we verify

NCT05884892

Egyptian Hypertrophic Cardiomyopathy Program

Recruiting now Last updated 1 June 2023
What this trial tests

trial in Hypertrophic Cardiomyopathy in 2,000 participants. Currently enrolling.

Timeline
1 January 2014
Primary endpoint
1 January 2030
1 January 2030

Quick facts

Lead sponsorMagdi Yacoub Heart Foundation
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,000
Start date1 January 2014
Primary completion1 January 2030
Estimated completion1 January 2030
Sites1 location across Egypt

Conditions studied

Sponsor

Magdi Yacoub Heart Foundation

Who can join

Eligibility, any sex, with Hypertrophic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Egyptian HCM program aims at defining incidence, severity, phenotype, genotype and determinants of the disease in Egypt, and providing state-of-the-art treatment strategies including medical, surgical and interventional procedures which are patient- and disease-specific.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hypertrophic Cardiomyopathy

Currently open trials in the same condition.

Other Magdi Yacoub Heart Foundation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05884892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing